HEALTHSTORY 1124· JUNE 20, 2026

Daraxonrasib Doubles Average Survival in Pancreatic Cancer, UCLA-Led Trial Shows

A UCLA-co-led international study presented May 31 at the American Society of Clinical Oncology annual meeting in Chicago reported that pancreatic cancer patients treated with daraxonrasib survived an average of 13.2 months — nearly double…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 1123Nuclear Bros: Silicon Valley's Young Founders Race to Restart American Atomic Power NEXT STORY 1125 →U.S. Confirms Second Strike on Iran Targeting Air Defenses as Oil Prices Surge

Keep reading

More from the desk.

48HEALTH

Readers debate doctor credentials, AI in the exam room, and surrogacy in STAT's First Opinion letters

When physician credentials, artificial intelligence in the exam room, and surrogacy generated enough reader mail to warrant a public reply, STAT published the letters. The health and life sciences publ

health1 MIN

69HEALTH

A drug for Angelman syndrome failed its final trial. Researchers say the science is not done.

A late-stage trial for an experimental Angelman syndrome drug came back negative this week, dealing a major blow to patients and to the company behind it. Late-stage, in clinical testing, means the final ro

health2 MIN

74HEALTH

Novartis heart drug pelacarsen fails its largest clinical trial

A closely watched drug for a common heart disease risk factor has failed in its biggest test. Pelacarsen, developed by Novartis, targets Lp(a), a particle made from lipids and proteins whose elevated concentrations in the blood raise the…

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk